INVO Bioscience, Inc. (NASDAQ:INVO) Q1 2021 Earnings Conference Call May 17, 2021 4:30 PM ET Company Participants Joe Diaz - Investor Relations Steve Shum - Chief Executive Officer Conference Call Participants Scott Henry - ROTH Capital Kyle Bauser - Colliers Securities John Heerdink - Vista Partners Operator Good afternoon and welcome to the INVO Bioscience reports First Quarter of Fiscal Year 2021 Financial Results Conference Call. All participants will be in listen-only mode. [Operator Instructions] Plea ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 INVO Bioscience, Inc. (Exact name of registrant as specified in its charter) | Nevada | 001-39701 | 20-4036208 | | --- | --- | --- | | (State or other jurisdiction | (Commission | (I.R.S. Employer ...

INVO Bioscience, Inc. (NASDAQ:INVO) Q4 2020 Earnings Conference Call March 30, 2021 4:30 PM ET Company Participants Robert Blum – Investor Relations-Lytham Partners Steve Shum – Chief Executive Officer Mike Campbell – Chief Operating Officer and Vice President of Business Development Conference Call Participants Kyle Bauser – Colliers Securities John Heerdink – Vista Partners Operator Good day and welcome to the INVO Bioscience reports Fourth Quarter and Fiscal Year 2020 Financial Results Conference Call. A ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION (State or other jurisdiction of incorporation or organization) WASHINGTON, D.C. 20549 FORM 10-K ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2020 INVO BIOSCIENCE, INC. (Exact name of registrant as specified in Charter) or Nevada 001-39701 20-4036208 (Commis ...

INVO Bioscience, Inc. (NASDAQ:INVO) Q3 2020 Results Conference Call November 19, 2020 4:30 PM ET Company Participants Robert Blum - Lytham Partners Steven Shum - CEO Michael Campbell - COO and Head of Business Development Conference Call Participants Operator Good afternoon and welcome to the INVO Bioscience Science Third Quarter fiscal year 2020 Financial Results Conference Call. All participants will be in a listen-only mode. [Operator Instructions] Please note, this even it being recorded. I would now li ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-39701 INVO Bioscience, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Nevada 20-4036208 (I.R. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 000-56094 INVO Bioscience, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Nevada 20-4036208 (I.R.S. Em ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 333-147330 INVO Bioscience, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Nevada 20-4036208 (I.R.S. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2019 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to INVO BIOSCIENCE, INC. (Exact name of registrant as specified in Charter) Nevada 333-147330 20-4036208 (State or other jurisdiction of incorporation or organization) (Commi ...

INVO Bioscience, Inc. (IVOB) Q3 2019 Results Earnings Conference Call November 21, 2019 11:00 AM ET Company Participants Robert Blum - Lytham Partners Steven Shum - CEO Michael Campbell - Company’s COO and VP of Business Development Conference Call Participants Operator Good morning everyone. And thank you for joining us on today’s INVO Bioscience Science Webcast. I’m Robert Blum of Lytham Partners and I will be your moderator for today’s event. Joining us on today’s event is the Company’s recently named Ch ...